Placebo News and Research

RSS

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for 2 years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study appearing in the December 25 issue of JAMA.

27 Dec 2013

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

The Finnish Degenerative Meniscal Lesion Study (FIDELITY) compared surgical treatment of degenerative meniscal tears to placebo surgery.

27 Dec 2013

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing in the December 25 issue of JAMA.

25 Dec 2013

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

A recent study led by researchers from the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center demonstrates that diflunisal, a generic anti-inflammatory drug, successfully reduced neurological decline and preserved the quality of life in patients with familial transthyretin amyloidosis. Diflunisal is an inexpensive and safe medication marketed over the past 40 years for arthritis and pain.

25 Dec 2013

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Synergy Pharmaceuticals Inc. today announced it has closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation.

24 Dec 2013

Study: Antidepressants not effective for bipolar disorder treatment

The use of antidepressants in the treatment of bipolar disorder remains controversial. Some studies and treatment guidelines suggest that antidepressant treatment for bipolar disorder may have the potential to increase the manic switch, while others recommend short-term antidepressant treatment and early discontinuation.

24 Dec 2013

Duration of common pediatric respiratory infections estimated

An international research team has systematically reviewed the literature to formulate up-to-date estimates of the duration of common childhood respiratory tract infections.

24 Dec 2013

Inosine drug raises blood and cerebrospinal fluid urate levels in Parkinson disease patients

The drug inosine appears to be a safe and effective way to raise blood and cerebrospinal fluid urate levels in patients with early Parkinson disease, suggesting it may be a potential strategy to slow the disability progression of the degenerative neurological disorder, according to a report published by JAMA Neurology, a JAMA Network publication.

23 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

Study supports use of two drugs for treating children with aggression and disruptive behavior

Prescribing both a stimulant and an antipsychotic drug to children with physical aggression and attention-deficit/hyperactivity disorder, along with teaching parents to use behavior management techniques, reduces aggressive and serious behavioral problems in the children, according to a study conducted by researchers at The Ohio State University Wexner Medical Center.

22 Dec 2013

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.

21 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis.

20 Dec 2013

Researchers reveal how metabolic system breaks down in obesity

Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials at the university could reverse obesity, Type 2 diabetes and fatty liver disease in humans.

20 Dec 2013

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014.

18 Dec 2013

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Led by University of Melbourne PhD candidate Cathy Watson also of the Royal Women's Hospital, the findings were published online in the British Journal of Obstetrics and Gynaecology.

18 Dec 2013

Selenium fails to protect NSCLC patients against second primary tumors

Selenium supplementation does not reduce the risk for second primary tumors in patients with resected non–small-cell lung cancer, researchers say.

17 Dec 2013

Oral garlic does not reduce vaginal thrush, study finds

In a world-first study, led by the University of Melbourne and the Royal Women’s Hospital, researchers have found garlic does not significantly reduce vaginal candida (thrush).

17 Dec 2013

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

Placebo News and Research

Nonsteroidal anti-inflammatory agent delays neuropathy progression, preserves quality of life

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Diflunisal drug reduces neurological decline in patients with familial transthyretin amyloidosis

Synergy Pharmaceuticals closes patient enrollment in plecanatide phase 2b clinical trial in IBS-C

Study: Antidepressants not effective for bipolar disorder treatment

Duration of common pediatric respiratory infections estimated

Inosine drug raises blood and cerebrospinal fluid urate levels in Parkinson disease patients

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Study supports use of two drugs for treating children with aggression and disruptive behavior

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

Researchers reveal how metabolic system breaks down in obesity

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Selenium fails to protect NSCLC patients against second primary tumors

Oral garlic does not reduce vaginal thrush, study finds

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News